LENZ Therapeutics
LENZ
63 hedge funds and large institutions have $80.7M invested in LENZ Therapeutics in 2022 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 11 increasing their positions, 14 reducing their positions, and 28 closing their positions.
4% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 28
0% more funds holding
Funds holding: 63 → 63 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.52% less ownership
Funds ownership: 8.96% → 7.44% (-1.5%)
21% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 14
57% less capital invested
Capital invested by funds: $186M → $80.7M (-$105M)
72% less call options, than puts
Call options by funds: $59K | Put options by funds: $210K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$3.5M |
| 2 |
Renaissance Technologies
New York
|
+$2.51M |
| 3 |
LCM
Laurion Capital Management
New York
|
+$1.83M |
| 4 |
Two Sigma Investments
New York
|
+$1.39M |
| 5 |
Millennium Management
New York
|
+$1.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$13.8M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$9.13M |
| 3 |
VA
VR Adviser
New York
|
-$8.22M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.41M |
| 5 |
BlackRock
New York
|
-$3.84M |
LENZ Hedge Fund Activity: Q2 2022 in Review
63 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in LENZ Therapeutics (LENZ) for Q2 2022, worth a combined $80.7M — down 57% from $186M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new LENZ positions and 28 closed out — a net gain of 1 holder — while 11 added to existing stakes and 14 trimmed.
The largest buyer was Tang Capital Management, opening a new position worth an estimated $3.5M. The largest seller was RA Capital Management, exiting entirely with an estimated $13.8M sold.
- 63 institutional investors held LENZ Therapeutics (LENZ) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $80.7M of LENZ Therapeutics stock for Q2 2022, down 57% quarter-over-quarter.
- 29 funds opened new LENZ Therapeutics positions in Q2 2022 and 28 closed out, a net change of +1 holder.
- The largest LENZ Therapeutics buyer in Q2 2022 was Tang Capital Management, an estimated $3.5M added.
- The largest LENZ Therapeutics seller in Q2 2022 was RA Capital Management, an estimated $13.8M sold.
Based on aggregated 13F filings for Q2 2022.